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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. Prevention and
control strategies require an improved understanding of SARS-CoV-2 dynamics. We did a
rapid review of the literature on SARS-CoV-2 viral dynamics with a focus on infective
dose. We sought comparisons of SARS-CoV-2 with other respiratory viruses including
SARS-CoV-1 and Middle East respiratory syndrome coronavirus. We examined laboratory
animal and human studies. The literature on infective dose, transmission and routes of expos-
ure was limited specially in humans, and varying endpoints were used for measurement of
infection. Despite variability in animal studies, there was some evidence that increased dose
at exposure correlated with higher viral load clinically, and severe symptoms. Higher viral
load measures did not reflect coronavirus disease 2019 severity. Aerosol transmission seemed
to raise the risk of more severe respiratory complications in animals. An accurate quantitative
estimate of the infective dose of SARS-CoV-2 in humans is not currently feasible and needs
further research. Our review suggests that it is small, perhaps about 100 particles. Further
work is also required on the relationship between routes of transmission, infective dose, co-
infection and outcomes.
Introduction
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by cor-
onavirus 2 (SARS-CoV-2) which is now pandemic. Several fundamental virologic concepts
relating to COVID-19 remain poorly understood such as the initiating event and infective
dose i.e. number of particles to cause a detectable infection. For understanding viral pathogen-
icity, determining the number of particles that trigger infection is crucial. A low infectious dose
could mean the organism is highly transmissible person-to-person and via touching contami-
nated surfaces [1]. Viral load is one of the main aspects of viral kinetics in infectious disease
transmission [2]. It can help develop prevention and control strategies and risk models of dis-
ease [2]. Little is known on whether viral load correlates with disease severity and progression.
Route of exposure to an infectious agent is also important [3]. Different outcomes from no
infection to subclinical or clinical infection can be observed after exposure to the infectious
agent [3]. It is unclear whether the number of particles on exposure is correlated with the
severity and outcome of disease, however for some infectious diseases a dose−response rela-
tionship between dose of infectious agent at exposure and outcome of disease has been
reported [4]. Understanding of these concepts requires experimental studies to complement
epidemiologic data that can provide limited insights into these matters. Improved understand-
ing of viral concepts of SARS-CoV-2 can promote more effective outbreak control strategies.
We did a rapid review of the evidence for the infectious dose, viral load, co-infection, route of
transmission and correlation with the outcome of SARS-CoV-2 infection. To help interpret the
limited data available we compared viral dynamics of SARS-CoV-2 with other respiratory
pathogens such as influenza virus, SARS-CoV-1 and Middle East respiratory syndrome
(MERS-CoV) viruses.
Methods
We identified relevant data for this review by searching databases including PubMed and
Google Scholar, using the terms ‘Infective dose’, ‘Respiratory viruses’, ‘SARS-CoV’, ‘MERS-
CoV’, ‘Aerosol’, ‘COVID-19’, ‘viral load’, ‘Coronavirus’, ‘Influenza virus’. The latest literature
search was performed on 1 September 2020 with no restriction on date of publication and
study design. We included articles published in English with full-text version available. We
did not limit our search to peer-reviewed journals.
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Result
We included 79 experimental and human studies exploring the
infective dose, viral load, route of administration, exposure and
outcome in respiratory viruses. We extracted data for respiratory
viruses including coronaviruses (Seasonal CoV, SARS-CoV-1,
SARS-CoV-2, MERS-CoV), influenza virus, rhinovirus, coxsack-
ievirus, adenovirus and respiratory syncytial virus (RSV).
Infective dose
The main methods for defining the infective viral dose is through
studies utilising dilution of virus studies for cytopathogenic effect
(CPE) in 50% of inoculated culture cells (known as tissue culture
infectious dose, or TCID50), or by counting plaque-forming units;
each plaque in a layer of host cells indicating colonisation by a
single virus particle (plaque forming unit− PFU) [5]. TCID50 is
the viral dose that induces either pathological changes or cell
death in 50% of inoculated tissue cultures. The viral plaque
assay is a quantitative measure of the number of particles that
form a plaque, estimating viral concentration in plaque-forming
units [6]. A virus titre of 0.7 PFU can be estimated as theoretically
equivalent to 1 TCID50, so given that most studies reported the
latter we converted the results for those reporting PFU [6]. For
determining the infectious dose (ID50) in humans the viral
administration should, ideally, be in controlled experiments.
Since patient safety concerns would usually make this unethical,
animal-based experimental studies are mostly used for simulating
infection in humans [7]. We have summarised in Tables 1 and 2
the infectious dose reported for some major human respiratory
viruses identified by either experimental infection in human
volunteers or laboratory animals.
Human studies on infective dose of SARS-CoV-2 and other
relevant viruses
Irrespective of the route of inoculation, some respiratory viruses such
as rhinoviruses and adenoviruses mostly cause asymptomatic or mild
respiratory symptoms in immunocompetent hosts. Influenza is one
of the most contagious and rapidly spreading viruses with a very
low infective dose [41]. Although other factors are important in
transmission of the virus, the minimum infective dose of SARS-
CoV-2 causing COVID-19 in humans is unknown it is assumed to
be low since the virus transmits rapidly and is more contagious
[42, 43]. The route of inoculation affects the response to viruses
[7]. Infective dose assessment in human studies requires intranasal
administration of the virus via drops or aerosols. Infection with
drops informs us about upper respiratory tract infection, while aero-
sols can inform about lower respiratory tract infection [7].
We found no experimental studies of this kind in humans but
observational studies. Nasopharyngeal and endotracheal samples
of SARS-CoV-2 infected patients showed no growth after eight
days post incubation in Vero cells. Median tissue culture infective
dose was calculated as 1780 TCID50/ml [44]. Isolation of
SARS-CoV-2 from oropharyngeal and nasopharyngeal sample of
one patient in the USA and inoculation in Vero cells shows that
SARS-CoV-2 can replicate rapidly and achieve 105 TCID50/mL
within 24-hour post-infection [45] (study not tabulated).
Although virus titre peaked at >106 TCID50/ml after 48 h post-
inoculation, major CPE (cytopathogenic effect) was observed
after 60 h post-inoculation [45]. This infective dose is much
higher than rhinovirus but lower than for influenza virus and
similar to coxsackievirus when administered nasally.
Table 1 shows human studies in healthy volunteers on other
relevant respiratory viruses.
(a) Coronavirus
The human ID50 for seasonal coronavirus subtype 229E that
causes mild common cold in humans was reported to be 13
TCID50 [8].
(b) Influenza
The infective dose for H1N1 strain of influenza virus by nasal
drop was 103 TCID50 (Table 1, B) [9]. For the H2N2 strain by
aerosol administration that TCID50 was 0.6–3.0 TCID50 [10],
higher than by intranasal drop (127–320 TCID50) [46]. For the
H3N2 strain by nasal drop was 1 × 107 TCID50 [11].
(c) Rhinovirus
The TCID50 of rhinovirus when administered by aerosols at
0.68 TCID50 was about 20 times greater than by nasal drops
(0.032 TCID50) [12].
Table 1. Infective dose of relevant respiratory viruses in humans
Virus Strain
Dose
Route of administration ReferencesTCID50 PFU
aCoronavirus HCoV-229E 13 9 NR Watanabe [8]
bInfluenza H1N1 1.0 × 103 700 IN Hayden [9]
H2N2 0.6–3 0.42–2.1 Aerosol Alford [10]
H3N2 1.0 × 107 7 000 000 IN Treanor [11]
cRhinovirus RV15 0.032 0.0224 IN Couch [12]
dAdenovirus Type 4 0.5 0.35 Aerosol Couch [13]
eCoxsackievirus A21-48654 6 4.2 IN Couch [12]
fRSV Ts-1 30–40 (33% infected) 21–28 IN Parrott [14]
Type 39 100 70 Aerosol Bischoff [15]
TCID50; %50 tissue infective culture dose, PFU; plaque-forming units, RSV; respiratory syncytial virus, NR; not reported, IN; intranasal.
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(d) Adenovirus
For Adenovirus type 4 the TCID50 was 35 TCID50 by intrana-
sal route and 0.5 TCID50 by aerosol [13]. In this study 6.6 parti-
cles by aerosol (corresponding to 462 particles by nasal drop)
were required to initiate infection in 50% of the population.
Furthermore, a high dose of virus by nasal drops was found to
cause infection in the lower intestinal tract [13].
(e) Coxsackievirus
TCID50 of coxsackievirus A21 strain was 6 TCID50 when
administered by intranasal droplet compared with 28–34
TCID50 by aerosol [12].
(f) Respiratory syncytial virus (RSV)
Attenuated vaccine strain of RSV, TS-1, at a dose of 30–40
TCID50 infected infants. This infectious dose of RSV is assumed
to be lower than with the wild strain because of its lesser virulence
through multiple passages in tissue culture [14]. Type-39 had a
TCID50 of 100 [15].
Animal studies
SARS-CoV-2
Table 2 summarises experimental animal studies on SARS-CoV-2.
(a) Ferret
Intranasal inoculation of 105.5TCID50 (221 359 PFU) of SARS-
CoV-2 virus presented raised body temperature and decreased
activity in ferrets [16]. One out of six ferrets that were infected
by intranasal route at a dose of 500 PFU showed signs of upper
respiratory tract viral replication. Meanwhile, all ferrets presented
with pulmonary histopathological features and viral RNA replica-
tion at higher doses (50 000– 5 000 000 PFU) [17, 18].
(b) Mice
An study on human angiotensin converting enzyme 2
(hACE2) transgenic mice after intranasal inoculation at a dose
of 105 TCID50 (70 000 PFU) of SARS-CoV-2 showed weight
loss and viral replication in the lungs [19]. Another study on
both young and aged hACE2 mice after infection at a dose of
400 000 PFU (≈5.71 × 105 TCID50) by intranasal route showed
mild weight loss (10%) and more severe histopathological features
of interstitial pneumonia in aged mice [20]. Mice infected by the
intragastric route at a dose of 4 000 000 PFU (≈5.71 × 106
TCID50) showed pulmonary infection in one of three mice [20].
Transgenic mice after aerosol inoculation of SARS-CoV-2 isolates
at a dose of 630 PFU showed viral RNA, interstitial pneumonia
and pulmonary infiltration after at least 25 min exposure to the
virus [21]. After intranasal infection with 21 000 PFU of
SARS-CoV-2, three out of six hACE2 mice died at 6 days post
infection [22]. Similarly 40% mortality in begg albino
laboratory-bred (BALB/c) mice was observed after intranasal
infection with SARS-CoV-2 at a dose of 100 000 PFU [23].
BALB/c mice showed viral replication and interstitial pneumonia
at a dose of 16 000 PFU by the intranasal route [24].
(c) Cynomolgus macaques
After aerosol inoculation at a dose of 48 600 PFU macaques
presented modest clinical signs, viral RNA and pulmonary patho-
logical features [28]. After inoculation at a dose of 700 000 PFU
(106 TCID50) of SARS-CoV-2 intranasally and intrathecally, cyno-
molgus macaques presented no clinical signs, however, histo-
pathological changes indicating diffuse alveolar damage and
viral replication were observed [29].
(d) Rhesus macaques
Rhesus macaques infected with SARS-CoV-2 at a dose of
700 000 PFU (106 TCID50) via ocular conjunctivae presented
mild pneumonia and higher viral RNA than those infected intra-
thecally, whereas no viral RNA was detected after exposure by the
intragastric route [30]. After inoculation at a dose of 2 600 000
TCID50 (1 820 000 PFU) of SARS-CoV-2 by the intranasal, intra-
tracheal, oral and ocular routes, macaques showed various range
of clinical signs including weight loss, piloerection, decreased
appetite, pallor and dehydration [31]. Exposure to higher doses
and correlation with signs of infection such as decrease in appetite
and response to stimuli as well as slight neutropenia and lympho-
penia was observed in a group of rhesus macaques that were
infected at a dose of 1 100 000 PFU (≈1.57 × 106 TCID50). Two
groups of rhesus macaques that were infected by intranasal and
intrathecal route at a dose of 110 000 PFU (≈1.57 × 105
TCID50) and 110 000 PFU (≈1.57 × 104 TCID50) presented mild
clinical disease. Histopathological features of pneumonia were
observed at a dose of 110 000 PFU [32]. Rhesus macaques
exposed by aerosol route at a dose of 28 700 PFU showed mild
clinical signs of pulmonary infection [28].
(e) African green monkey
All three African green monkeys exposed to 36 000 PFU by the
aerosol route showed clinical signs of pulmonary disease [28].
African green monkeys inoculated by combined intranasal and
intrathecal routes at a dose of 500 000 PFU (≈7.14 × 105
TCID50) showed histopathological features of pulmonary lesions
and no overt clinical signs of disease [33]. At a dose of 3 000 000
PFU (≈4.28 × 106 TCID50) they showed efficient viral replication
and respiratory signs of infection [34]. Two African green mon-
keys exposed at a dose of 2000 PFU by the aerosol route and
3 610 000 PFU by combined route of intranasal, thecal, ocular
and oral showed signs of acute respiratory distress syndrome
(ARDS), increased level of interleukin 6 (IL6) and cytokine
storm [35].
(f) Hamsters
In two groups of juvenile and adult hamsters infected by intra-
nasal and ocular routes with SARS-CoV-2 at a higher and lower
dose of 105.6 PFU (≈5.68 × 105 TCID50) and 1000 PFU (≈1.42 ×
103 TCID50), respectively, higher dose infected hamsters presented
more severe lung complications, earlier weight loss and earlier
pneumomediastinum than the lower dose group [36]. Hamsters
that were intranasally inoculated at a dose of 56 000 PFU showed
weight loss and viral shedding [37]. After intranasal infection at a
dose of 100 000 PFU hamsters showed both clinical presentation
and viral RNA [38]. Immunosuppressed hamsters after intranasal
inoculation at doses of 100 and 1000 PFU showed extreme weight
loss whereas death was observed in those exposed to 10 000 PFU [39].
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Table 2. Experimental studies on the infective dose of coronaviruses in various mammals
Virus Host Dose (PFU) Route of inoculation
Numbers and/or %, signs
of infection References
SARS-CoV-2 aFerret 221 359 IN 6/6 Kim [16]
500 IN 16.7,1/6 Ryan [17]
50 000 IN 6/6
5 000 000 IN 6/6
420 000 IN 4/4 Richard [18]
SARS-CoV-2 bhACE2 mice 70 000 IN 36.8,7/19 Bao [19]
HCoV-OC43 400 000 IN 3/3 Sun [20]
4 000 000 IG 1/3
630 Aerosol 2/2 Bao [21]
21 000 IN 50% Lethal Jiang [22]
100 000 IN 40% Lethal Dinnon [23]
BALB/c mice 16 000 IN 3/3 Gu [24]
BALB/c and C57B6 mice 70 000 IP/IC 100% Lethal Jacomy [25]
BALB/c mice 70 IC 100% Lethal Shen [26]
SARS-CoV-1 tgMice 280 IN NR Watanabe [8]
MERS-CoV tgMice 0.7 IN NR Tao [27]
7 IN 50% Lethal
SARS-CoV-2 cCynomolgus macaques 48 600 Aerosol 4/4 Johnston [28]






Numbers and/or %, signs of
infection References
SARS-CoV-2 dRhesus macaques 700 000 IO 2/2 Deng [30]
IT 1/1
IG 0/2
1 820 000 IN/IT/IO/Oral 8/8 Munster [31]
11 000 IN/IT 3/3 Chandrashekar [32]
110 000 IN/IT 3/3
1 100 000 IN/IT 3/3 Johanston [28]
28 700 Aerosol 4/4
SARS-CoV-2 eAfrican green monkeys 38 000 Aerosol 3/3 Johanston [28]
500 000 IN/IT 6/6 Woolsey [33]
3 000 000 IN 6/6 Cross [34]
2000 Aerosol 2/2 Blair [35]
3 610 000 IO/IT/IN/Oral 2/2
SARS-CoV-2 fSyrian hamster 398 107 IN/IO 4/4 Imai [36]
1000 IN/IO 4/4
56 000 IN 3/3 Sia [37]
100 000 IN 75,24/36 Osterrieder [38]
Immunocompromised syrian
hamster
100 IN 10/10 Brocato [39]
1000 IN
10 000 IN 40% Lethal
gBats 70 000 IN 78,7/9 Schlottau [40]
TCID50, %50 tissue infective culture dose; PFU, plaque-forming units; tgMice, transgenic mice; hACE2, human angiotensin converting enzyme 2, BALB/c; begg albino laboratory-bred mouse,
IN; intranasal, IG; intragastric, IO; intraocular, IT; intrathecal, IC; intracerebral, IP; intraperitoneal, NR; not reported.
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(g) Bats and other animals
Intranasal inoculation of 105 TCID50 (70 000 PFU) of
SARS-CoV-2 isolates into fruit bats, pigs, chickens, cats, dogs
(data not tabulated for the latter four species) showed no clinical
signs and viral RNA replication in except slight viral RNA and
shedding in cats and bats [40, 47].
Other coronaviruses
We examined findings on other coronaviruses, including seasonal
CoV, SARS-CoV-1 and MERS-CoV for relevant insights. Two
groups of BALB/c mice and c57 black strain 6 (C57BL/6) mice
after infection with HCoV-OC43 at a dose of 105 TCID50
(70 000 PFU) by intraperitoneal and intracerebral route showed
100% lethality at 8 days [25]. However, at a dose of 104–105
TCID50 (7000– 70 000 PFU) they presented no clinical signs
and viral RNA by intraoral route and mild signs of infection by
intranasal route at 21 days postnatal [25]. In another study,
12-day-old BALB/c mice exposed by the intracerebral route at a
dose of 100 TCID50 (70 PFU) of wild-type HCoV-OC43 showed
100% lethality 4 days later [26]. Estimated infectivity of
SARS-CoV-1 was comparable to other coronaviruses including
HCoV-229E, a causative agent for a mild cold in humans. ID10
and ID50 of SARS-CoV-1 were reported as 43 and 280 PFU
(400 TCID50) in an experimental study [8]. A study on transgenic
mice reported the ID50 of MERS-CoV as <1 TCID50 and LD50 as
10 TCID50 [27]. Transgenic mice that were infected with MERS
by the intranasal route presented signs of infection at a dose
between 100 and 500 000 PFU (≈142 and ≈7.14 × 105 TCID50)
[48, 49].
Transmission route, exposure rate and correlation with
outcome
SARS-CoV-2 transmission is thought to be mainly through
respiratory droplets and fomites rather than through aerosols car-
ried over long distances [50]. There are questions about whether
the size of the infectious dose of SARS-CoV-2 and its route of
transmission correlates with disease severity.
SARS-CoV-2 was not thought to be transmitted long distances
by an aerosol in 75 465 COVID-19 patients in China [51]. A study
on aerosol distribution of SARS-CoV-2 in Wuhan hospital
reported the maximum distance of transmission as 4 m in hos-
pital wards. Reflecting this, an increased risk of positivity at sam-
pling site and objects observed in patients’ treatment areas
(40.6%) than office areas of physicians (12.5%) [52].
SARS-CoV-1 transmission is thought to be increased by 20.4-
fold when people have at least exposure for >30 min and distance
of <1 m with infected patients [53]. However, a safer physical
distance to avoid transmission of SARS-CoV-2 is 1 m as recom-
mended by WHO and approximately as 2 m by CDC [54, 55].
Small droplets can, nonetheless, be found at a distance of 7–8 m
away [56]. The rate of SARS-CoV-2 transmission was increased
by an estimated 18.7-fold in an enclosed area compared with
the outdoor environment [57]. Transmission of SARS-CoV-2
via contaminated surfaces or aerosolisation was observed in clus-
ter analysis of COVID-19 patients [58].
During the SARS-CoV-1 outbreak in 2003 the higher risk of
infection was correlated with the amount and setting of exposure
[53]. In the Amoy-Garden housing complex in Hong Kong, the
lower concentrations of the virus explained the lower risk of infec-
tion in the upper floors [59]. It was estimated that the apartment’s
residents were exposed to 16–160 PFU (≈22.8–228 TCID50) per
person depending on the floor [8].
Given the absence of direct information about SARS-CoV-2,
findings from other respiratory viruses and in animals may pro-
vide clues. The potential of airborne, aerosol transmission of
SARS-CoV-2 was observed in ferrets and cats [16, 60]. Aerosol
inoculation with the H3N2 strain of sub-lethal influenza
virus in laboratory mice, presented exacerbated mortality and
morbidity, pulmonary infiltration and inflammation, as well as
6-fold higher levels of IL-6 expression in the lungs compared to
intranasally inoculated mice [61]. Consistently, African green
monkeys infected by the aerosol route of SARS-CoV-2 (Table 2)
presented with ARDS, increased level of IL6, and cytokine
storms [35].
Increased exposure to the influenza virus, presumably reflect-
ing increased infective dose, was correlated with disease progres-
sion [62]. In addition to studies of SARS-CoV-2 infected ferrets,
rhesus macaques and hamsters [17, 32, 36, 39] studies on labora-
tory adapted mice infected with HCoV-OC43, SARS-CoV-1 and
MERS-CoV reported increased morbidity and lethality with
increasing dose at exposure [8, 48, 49].
SARS-CoV-2 viral load and outcome
COVID-19 has lower morbidity and mortality, but greater infect-
ivity, compared with SARS and MERS [63]. The serial interval,
the duration of the symptoms between the onset of symptoms
in an index case and the secondary case, of COVID-19 together
with viral shedding results suggest much transmission occurs
early, even before onset of symptoms [64, 65]. This interval is
about 3 days for influenza virus [66], 4 days for SARS-CoV-2
[64], 8.4 days for SARS-CoV-1 [67] and 14.6 days for
MERS-CoV [68]. This means that infected people with
SARS-CoV-2 and influenza can spread the virus faster than
SARS-CoV-1 and MERS-CoV. Most COVID-19 studies show
the highest viral load before or at and shortly after the onset of
symptoms [65, 69–71], which may account for the rapid spread-
ing of disease [72, 73]. The high viral load in throat swabs at or
just before onset of symptoms suggests that 44% of transmission
can occur in the asymptomatic stages [70]. SARS-CoV-2 and
influenza virus share a similar pattern of viral shedding
[29, 65]. There is correlation between higher viral load and the
severity of COVID-19 [74, 75]. Patients with severe symptoms
of COVID-19 in one study presented 60 times higher viral load
and prolonged viral shedding than patients with mild symptoms
[76]. In another study higher viral load was not correlated with
outcomes including ICU admission, mortality and oxygen require-
ment in hospitalised patients [77]. In a study on 4172 patients,
higher viral loads were observed in the first phase of the outbreak
and the first phase of disease. The same study reported lower viral
loads in ICU patients than patients in other wards [78].
A similar viral load was observed among different age groups
in one study [78] while another study found a higher viral load in
children aged <5 years than adults [79]. The viral loads in asymp-
tomatic patients were similar to those in patients with
mild-to-moderate COVID-19 [65]. Prolonged viral shedding, ini-
tial high viral load and increased risk of transmission in the early
stage of disease was also observed in patients with seasonal cor-
onavirus (OC43 and 229E) [80]. Patients with single seasonal cor-
onavirus had a higher viral load than patients with co-infection
[81]. Children with high viral loads of seasonal coronavirus were
found to have an increased risk of symptomatic infection [80].
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Studies on hamsters and African green monkeys reported no
correlation between viral load and initial exposure dose of
SARS-CoV-2 [35, 36] and SARS-CoV-1 [36, 82]. In contrast
viral load and inoculating dose were associated in laboratory
mice that were infected with SARS-CoV-1 [83] respiratory syncyt-
ial virus (RSV) [84] and influenza virus [85].
During the SARS-CoV-1 outbreak at Amoy Gardens complex
higher viral loads were detected in residents living in units adja-
cent to the index case indicating a link with exposure dose [86].
Inter-study and inter-species variability highlight that correlation
of viral load and dose at exposure is not unequivocal.
Discussion
Effective prevention and control strategies in the pandemic of
COVID-19 require understanding of infective dose, transmission
and coinfection. We found limited evidence on these points
requiring us to examine the data for other relevant viruses and
to combine observations on animals and humans. In humans
(Table 1) the infective dose varies greatly by virus and route of
administration. However, for coronavirus and influenza, mostly
hundreds or even more virus particles are required to cause an
infection. Similarly, in animals (Table 2) the infective dose varies
greatly by species and by route of administration. Our review may
help in selection of best animal models for experimental studies.
The infective dose is generally large, with hundreds and even mil-
lions of virus particles being required to induce disease. We esti-
mate that the infective dose for SARS-CoV-2 is probably lower
than for influenza virus (1000 TCID50) as it is more contagious
with a slightly higher R0. The only human study on a coronavirus
we found was on HCoV-229E with the TCID50 comparison was
13 [8]. The infective dose in humans for SARS-CoV-2 was esti-
mated as 100 particles based on computational analysis of naso-
pharynx in transmission and inhalation of droplets [87]. In
animals the minimum dose of SARS-CoV-2 that infected
immunocompromised hamsters were also 100 particles [39],
whereas healthy ferrets and transgenic mice were infected at
slightly higher dose of 500 particle by nasal [17] and 630 particles
by aerosol route [21]. Possibly the higher value of 100 particle can
be used as a potential surrogate for estimating the minimum
infective dose of SARS-CoV-2 in humans.
The findings of this study are relevant to the science under-
lying the use of respiratory mask in preventing transmission of
viral particles [88]. The data summarised here and in Table 2
shows that the true measurement of infectious dose in animals
and extrapolation to human is not possible. First, none of the ani-
mal studies reported the same clinical presentations and path-
ology after infection with SARS-CoV-2, and outcomes were
highly variable as in humans. Second, different endpoints used
for the measurement of infection, meanwhile susceptibility of ani-
mals can largely vary dependent on various species, ACE2 expres-
sion, age and comorbidities. Third, the route of inoculation can
largely affect the response of animals to infection. All the animals
infected by aerosol and other routes of exposure presented signs
of infection whereas animals exposed by the intragastric route
mostly remained asymptomatic (intranasal route being intermedi-
ate). In animals, the infective dose is generally lower with aerosol
transmission than other routes. The infective dose in human
could be lower than currently believed if transmission by aerosol
is important. Moreover, aerosol transmission can allow the virus
to penetrate into the lower respiratory tract of humans and cause
severe symptoms [7].
The route of infection can impact on the induction of innate
and adaptive immune responses [61]. Little is known about the
host immune response following different routes of infection
with SARS-CoV-2. Higher viral load is not necessarily correlated
with more severe symptoms, with some studies finding higher
viral load in mildly symptomatic or asymptomatic stages of dis-
ease [72, 77, 78]. This suggests a decline in viral load as the disease
progresses [77, 78].
COVID-19 shares important features with influenza in serial
interval of disease, clinical presentation, transmission route,
viral load, infective dose, viral shedding and correlation with out-
come. Studies on influenza virus suggest a correlation between
increasing body mass index (BMI) and increased aerosol shedding
through increased frequency of small airway closure and reopen-
ing [89]. High BMI is associated with critical illness and severity
of symptoms in patients with COVID-19 and influenza [90, 91].
Exhaled breath of symptomatic patients with influenza can trans-
mit an estimated 33 particles per minute in aerosol [89]. Twenty
minutes of exposure would be required for the exposure to the
median infective dose of H1N1 subtype. Similarly, almost 25 parti-
cles per minute (630 particles in 25min) in aerosol were required to
cause SARS-CoV-2 infection in hACE2 mice [21]. Exposure for a
similar period to SARS-CoV-2 exhaled in normal breathing of
infected patients could lead to the inhaling of our estimated hun-
dreds of SARS-CoV-2 particles by aerosol, thus complementing
infection by fomites and droplets. However, further studies are war-
ranted to examine infective dose by the aerosol route and its correl-
ation with COVID-19 severity and immune response both in
animals through experiments and humans through observation.
Conclusion
SARS-CoV-2 has distinct features as well as commonalities com-
pared with other similar respiratory pathogens justifying further
experimental and observational studies concentrating on trans-
mission, exposure, the infective dose, viral load, virus shedding
and the synergistic effect of viral dose and route of exposure
and co-infection of SARS-CoV-2 with one or more respiratory
pathogens. This review has merely laid the foundation in the
study of this topic which is important for the development of
rational public health strategies to minimise spread of infection.
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